Irinotel 40mg Injection contains Irinotecan, a potent chemotherapeutic agent used primarily in the treatment of metastatic colorectal cancer. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication and transcription, leading to cancer cell death. It is administered intravenously, typically as part of combination chemotherapy regimens such as FOLFIRI (folinic acid, fluorouracil, and irinotecan). The dosage and administration schedule depend on the patient’s clinical condition, prior treatment history, and tolerability. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, and alopecia, with severe diarrhea necessitating prompt management to prevent dehydration and electrolyte imbalance. Irinotel 40mg Injection requires careful monitoring of hematologic parameters and liver function tests during therapy. Dose adjustments may be necessary in patients with hepatic impairment or significant toxicity. It is contraindicated in patients with known hypersensitivity to irinotecan or its components. Due to its potential for severe myelosuppression and gastrointestinal toxicity, administration should be performed under strict medical supervision with appropriate supportive care measures. Irinotel 40mg Injection represents a critical component in the management of advanced colorectal cancer, contributing to improved survival outcomes when integrated into multidisciplinary treatment protocols.